Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.
Cultures of Escherichia coli were exposed to nalidixic acid in an in vitro model in which the conditions of drug-organism interaction resembled those of bacterial cystitis treatment. Results obtained in this way suggested that emergence of bacterial resistance should not be a major problem in treatment of uncomplicated urinary infection; such cases might indeed respond to a less intensive course of treatment than is usual. More prolonged, high-dosage therapy with nalidixic acid may be required for patients with more complicated infections if the risk of failure from the emergence of bacterial resistance is to be minimized.
D003556:Cystitis / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects*; D009268:Nalidixic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy*
D009268:Nalidixic Acid